Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Language
Publication year range
1.
Arq Gastroenterol ; 58(1): 32-38, 2021.
Article in English | MEDLINE | ID: mdl-33909794

ABSTRACT

BACKGROUND: Intravenous (IV) use of proton pump inhibitors (PPIs) is advised only in cases of suspected upper gastrointestinal bleeding (UGIB) or impossibility of receiving oral medication, although there has been a persistent practice of their inappropriate use in health institutions. OBJECTIVE: The purpose of our study was to measure the inappropriate use of IV PPIs in a high complexity hospital in Brazil and to estimate its costs. METHODS: Retrospective study of 333 patients who received IV omeprazole between July and December of 2018 in a high complexity hospital in Brazil. RESULTS: IV omeprazole was found to be appropriately prescribed in only 23.4% patient reports. This medication was administered mainly in cases of suspected UGIB (19.1%) and stress ulcer prophylaxis in patients with high risk of UGIB unable to receive medication orally (18.7%). It was observed a statistically significant association between adequate prescription and stress ulcer prophylaxis in patients with high risk of UGIB unable to receive medication orally; patient nil per os with valid indication for PPIs usage; prescription by intensive care unit doctors; prescription by emergency room doctors; intensive care unit admission; evolution to death; sepsis; and traumatic brain injury (P<0.05). On the other hand, inadequate prescription had a statistically significant association with surgical ward prescription and non-evolution to death (P<0.05). The estimated cost of the vials prescribed inadequately was US$1696. CONCLUSION: There was a high number of inappropriate IV omeprazole prescriptions in the studied hospital, entailing greater costs to the institution and unnecessary risks.


Subject(s)
Omeprazole , Proton Pump Inhibitors , Brazil , Hospitals , Humans , Retrospective Studies
2.
Arq. gastroenterol ; 58(1): 32-38, Jan.-Mar. 2021. tab
Article in English | LILACS | ID: biblio-1248997

ABSTRACT

ABSTRACT BACKGROUND: Intravenous (IV) use of proton pump inhibitors (PPIs) is advised only in cases of suspected upper gastrointestinal bleeding (UGIB) or impossibility of receiving oral medication, although there has been a persistent practice of their inappropriate use in health institutions. OBJECTIVE: The purpose of our study was to measure the inappropriate use of IV PPIs in a high complexity hospital in Brazil and to estimate its costs. METHODS: Retrospective study of 333 patients who received IV omeprazole between July and December of 2018 in a high complexity hospital in Brazil. RESULTS: IV omeprazole was found to be appropriately prescribed in only 23.4% patient reports. This medication was administered mainly in cases of suspected UGIB (19.1%) and stress ulcer prophylaxis in patients with high risk of UGIB unable to receive medication orally (18.7%). It was observed a statistically significant association between adequate prescription and stress ulcer prophylaxis in patients with high risk of UGIB unable to receive medication orally; patient nil per os with valid indication for PPIs usage; prescription by intensive care unit doctors; prescription by emergency room doctors; intensive care unit admission; evolution to death; sepsis; and traumatic brain injury (P<0.05). On the other hand, inadequate prescription had a statistically significant association with surgical ward prescription and non-evolution to death (P<0.05). The estimated cost of the vials prescribed inadequately was US$1696. CONCLUSION: There was a high number of inappropriate IV omeprazole prescriptions in the studied hospital, entailing greater costs to the institution and unnecessary risks.


RESUMO CONTEXTO: Atualmente, o uso intravenoso (IV) dos inibidores de bomba de prótons (IBPs) é indicado em poucas situações, como em casos de hemorragia digestiva alta ou impossibilidade de recebê-los via oral. Há diversos estudos mostrando o uso excessivo desse fármaco, na forma intravenosa, desnecessariamente e acarretando altos custos aos hospitais. OBJETIVO: Avaliar as indicações, posologias, duração do tratamento e custos das prescrições de omeprazol intravenoso. MÉTODOS: Estudo retrospectivo de 333 pacientes que receberam omeprazol intravenoso entre julho a dezembro de 2018 em um hospital de alta complexidade no Brasil. RESULTADOS: A prescrição de omeprazol intravenoso foi considerada totalmente adequada em apenas 23,4% das prescrições analisadas. O medicamento foi administrado principalmente em casos de suspeita de hemorragia digestiva alta (HDA) (19,1%) e profilaxia de úlcera de estresse em paciente com alto risco de HDA impossibilitado de receber via oral (18,7%). Foi observada associação estatisticamente significativa entre prescrição adequada e profilaxia de úlcera de estresse em paciente com alto risco de HDA impossibilitado de receber medicamento via oral; paciente em nil per os com indicação válida de IBPs; prescrição por médico da UTI; prescrição por médico do pronto atendimento; admissão na UTI; evolução a óbito; sepse; e traumatismo cranioencefálico (P<0,05). Já a prescrição inadequada teve associação estatisticamente significativa com prescrição por setor cirúrgico e a não evolução a óbito (P<0,05). O custo estimado do total de ampolas prescritas inadequadamente foi de US$1696,00. CONCLUSÃO: Houve um elevado número de prescrições de omeprazol intravenoso inadequadas no hospital estudado, acarretando um custo elevado para a instituição.


Subject(s)
Humans , Omeprazole , Proton Pump Inhibitors , Brazil , Retrospective Studies , Hospitals
3.
An Acad Bras Cienc ; 92(4): e20190981, 2020.
Article in English | MEDLINE | ID: mdl-32844989

ABSTRACT

An emerging area in schizophrenia research focuses on the impact of immunomodulatory drugs such as melatonin, which have played important roles in many biological systems and functions, and appears to be promising. The objective was to evaluate the effect of melatonin on behavioral parameters in an animal model of schizophrenia. For this, Wistar rats were divided and used in two different protocols. In the prevention protocol, the animals received 1 or 10mg/kg of melatonin or water for 14 days, and between the 8th and 14th day they received ketamine or saline. In the reversal protocol, the opposite occurred. On the 14th day, the animals underwent behavioral tests: locomotor activity and prepulse inhibition task. In both protocols, the results revealed that ketamine had effects on locomotor activity and prepulse inhibition, confirming the validity of ketamine construction as a good animal model of schizophrenia. However, at least at the doses used, melatonin was not able to reverse/prevent ketamine damage. More studies are necessary to evaluate the role of melatonin as an adjuvant treatment in psychiatric disorders.


Subject(s)
Dietary Supplements , Melatonin , Schizophrenia , Animals , Behavior, Animal , Disease Models, Animal , Melatonin/pharmacology , Rats , Rats, Wistar , Rodentia , Schizophrenia/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...